Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upifitamab rilsodotin in NaPi2b-expressing solid tumors
NCT06517433Phase 1Completed
- Sponsor
- Mersana Therapeutics
- Start
- Dec 2017
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of upifitamab rilsodotin in ovarian cancer and non-small cell lung cancer (NSCLC), sponsored by Mersana Therapeutics. Primary endpoints: Maximum Tolerated Dose or Recommended Phase 2 Dose up to 36 weeks and Safety and Tolerability. Started Dec 2017; status: completed.
02
Drugs
upifitamab rilsodotin
03
Conditions
ovarian cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06517433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06517433.